Key Points {#FPar1}
==========

Accelerated molecular characterization of rare disease cases and the advent of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) technology promise to enable rapid therapy development for many rare genetic diseases.The adoption of editing technology reduces the time from conception to evaluation of advanced therapy approaches compared to gene addition, encouraging an unprecedented number of research groups and studies to focus on rare diseases.As CRISPR/Cas-based tools are customized to tackle rare diseases in clever ways, the results reveal and help address remaining unknowns and obstacles in the clinical translation of the new technology, including those concerning efficiency, specificity, delivery, immunity, preservation of stemness, and avoiding malignant transformation.

Rare Diseases: Towards Curative Treatments {#Sec1}
==========================================

Rare Diseases and Rarer Disease Expertise {#Sec2}
-----------------------------------------

Rare diseases are common and ubiquitous, and for decades rare therapies were anything but well done. As this introductory sentence employs puns commonly used in the rare disease literature, its two parts summarize the double challenge faced by society and patients, respectively. First, it is a widely accepted estimate that globally between 6000 and 8000 individually rare diseases across all therapeutic areas affect between 8 and 10% of the population and therefore taken together pose a widespread and pervasive challenge \[[@CR1], [@CR2]\]. Second, rare disease patients are frequently treated suboptimally, if they receive treatment at all, because few clinicians have the opportunity to build up disease expertise for rare diseases. Consequently, many a rare disease patient does not receive a definite diagnosis or is initially misdiagnosed due to often missing molecular (causative) information for the disease in question, clinical features that overlap with other, more common afflictions, and limited global access by the treating physicians to relevant data \[[@CR2]--[@CR4]\]. Many rare diseases have early or prenatal onset, making prompt and appropriate treatment all the more important. However, where even diagnosis is difficult, disease management often relies on ad hoc symptomatic treatments or repurposed medicines developed for other diseases, so that an estimated 94% of rare diseases are without an approved treatment \[[@CR5], [@CR6]\]. This problem is exemplified by the ongoing search for effective treatments for two relatively prominent rare diseases, Shwachman--Diamond syndrome and cystic fibrosis, as reviewed by Bezzerri and Cipolli \[[@CR7]\] and by Cabrini \[[@CR8]\], respectively, in this issue of *Molecular Diagnosis and Therapy*. Moreover, a cure is only available where stem cell or organ transplantation is feasible for the tissues affected and where a compatible donor can be identified \[[@CR9]--[@CR12]\]. Accordingly, the average standard of care for rare disease patients is suboptimal, at high long-term cost to national health budgets and individual health. In response, governments try to incentivize investment in rare disease drug development by introducing orphan drug legislation that lowers regulatory thresholds for clinical translation \[[@CR13]\] and invest in the collaboration of international rare disease experts, such as through the International Rare Diseases Research Consortium (IRDiRC) \[[@CR14]\]. Specialty international networks of rare disease expertise, including the nascent European Reference Networks (ERNs) or other international networks complement this effort \[[@CR2], [@CR15]\]. Likewise, rare disease expertise is pooled by establishing government-funded or co-funded information portals, such as the Genetic and Rare Diseases Information Center (GARD) run by the US National Center for Advancing Translational Sciences \[[@CR16], [@CR17]\] and the European Orphanet \[[@CR18]\], complemented by academic disease-specific databases \[[@CR19], [@CR20]\] and patient portals such as the National Organization for Rare Disorders (NORD) and EURORDIS (Rare Diseases Europe) \[[@CR21], [@CR22]\]. Most rare diseases are not and cannot be in the standard medical curriculum, but at ever increasing speed the knowledge base increases and becomes available to anyone willing to look. This is particularly true for the assumed vast majority of classifiable rare diseases that have a genetic cause, with key developments the rapid discovery of novel causative mutations for rare diseases by massively parallel sequencing \[[@CR23]\] and adoption of global variant database and nomenclature standards to make the information universally accessible and interpretable \[[@CR14], [@CR19]\]. While one of the major contributions of rapid variant discovery to reducing the global burden of disease is seen in rare disease prevention \[[@CR24]\], it likewise provides the foundation for stratified if not personalized rare disease treatments by gene therapy.

Teething Troubles of Gene Therapies for Rare Diseases {#Sec3}
-----------------------------------------------------

As reviewed by us and others in this issue of *Molecular Diagnosis and Therapy* \[[@CR25], [@CR26]\], gene therapy for rare diseases has achieved remarkable successes for several rare diseases, including curative treatments. As a prerequisite for success, robust and clearly defined clinical trial design is imperative in order to deal with the unique challenges inherent to rare diseases. These challenges include small and highly fragmented study populations and the difficulty of setting clear clinical endpoints, often in the absence of control groups, without in-depth understanding of the disease state, and in the face of high heterogeneity of the disease phenotype and further complications unique to rare diseases \[[@CR27]\]. Despite these difficulties, several successful trials have already resulted in orphan drug designations for rare diseases as an important milestone on the road to market approval. For instance, market approval was achieved for Glybera to treat lipoprotein lipase deficiency (EMEA/H/C/002145) in 2012, for Strimvelis® to treat adenosine-deaminase-linked severe combined immunodeficiency (ADA-SCID) (EMEA/H/C/003854) in 2016 \[[@CR2]\], and for Luxturna™ to treat mutation-associated retinal dystrophy in the USA in late 2017 and in the European Union (EU) in late 2018 (EMEA/H/C/004451) \[[@CR29]\]. Glybera has since been withdrawn from the market for lack of profitability, indicating a persistent and worrisome problem in the provision of ultra-rare disease drugs despite high development cost and uncertain reimbursement models, in the case of Glybera exacerbated by limited safety and efficacy data that prevented full market penetration \[[@CR30], [@CR31]\]. By contrast, Strimvelis® and Luxturna™ have both provided substantial benefits to patient cohorts in the absence of adverse events after years of follow-up, but their continued provision will once more depend on their profitability. In view of the economic lessons learnt \[[@CR30]\], gene therapy companies will thus preferentially seek market approval of drugs for more prominent rare diseases. In consequence, and unless other funding mechanisms are developed, the current trend holds the danger that a wealth of competing treatments will become available for more prominent rare diseases, whereas a multitude of ultra-rare diseases will be left out. Unless development costs are vastly reduced, gene therapy for those diseases would then merely and sadly remain an academic exercise. One factor that will make translation more affordable is the maturation of the corresponding regulatory framework at national and international level \[[@CR32]\], which already provides a level of certainty about the ground rules for translation and facilitates compliance across jurisdictions and harmonization of the development and approval process. Moreover, curative treatments, such as Strimvelis® and Luxturna™, are usually based on permanent gene addition, which provides *trans*-acting components or a functional copy of the defective gene, either as an integrating transgene or, for non-dividing cells, as a stable episome \[[@CR25]\]. Despite the apparent simplicity of the concept, years if not decades of study of disease and regulatory mechanisms are usually required in order to achieve both efficient delivery and stable physiological expression of the therapeutic transgene. For many rare diseases, required insights into the underlying disease mechanism are insufficient to allow such development, even if funding were available.

Gene Therapy Version 2.0 {#Sec4}
------------------------

As more rare disease therapies based on gene addition advance from clinical trials toward market approval, a new wave of treatments based on gene editing technology are being developed, moving from preclinical studies to their first clinical trials. A slow development at first, based on zinc finger nucleases and other hard-to-design tools, the advent of transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) RNA-guided nucleases (RGNs) has led to recently accelerated development and a veritable explosion of tools and rare disease targets \[[@CR25]\]. However, as permanent gene addition by genome integration has inherent risks, such as those of insertional mutagenesis, so does gene editing. First, target recognition is error-prone to some degree, so that any editing application may introduce changes at hard-to-predict off-target sites, dependent on similarities to the on-target recognition sequence. For each editing tool, the risk of off-target modifications therefore needs to be assessed comprehensively early on and potentially eliminated by changing the tool or recognition site. Second, the pre-existing humoral and cell-mediated adaptive immunity to Cas9, as a common environmental antigen, poses the risk of triggering widespread immune responses in patients receiving CRISPR/Cas9-based gene therapy, at least in in vivo applications of these tools \[[@CR33]--[@CR35]\]. The third and fourth risks relate to gene editing by designer nucleases being universally based on the introduction of double-strand breaks (DSBs) in the genome as triggers of repair by the efficient but imprecise non-homologous end-joining (NHEJ) mechanism or the inefficient but precise homology-directed repair (HDR) mechanism \[[@CR25]\]. Specifically, efficient induction of DSBs may cause P53-mediated apoptosis for cycling cells \[[@CR36]--[@CR38]\], leading to a principally but not widely proven enrichment for P53-deficient, and thus more cancer-prone, cells by DSB-mediated editing. Additionally, and of still more acute concern, even single DSBs may lead to wide-ranging deletions or chance recombination events involving the on-target site \[[@CR39]\], and as long as the frequency and pattern of such events is not clarified, application of gene editing to rare diseases that are also manageable with palliative treatments may be premature. While the risk of off-target activity cannot be eliminated at the design stage but rather only assessed later on, at least any problems relating to DSBs may be avoided by a new class of editing tools: base editors. Based on the CRISPR/Cas platform and allowing certain targeted base substitutions by chemical base editing, base editors act independent from DSBs and thus without elevating the risk of chromosomal rearrangements or cancer-prone cells \[[@CR40], [@CR41]\].

Importantly, and although gene editing tools may be employed in a variety of other strategies, the option of targeting and correcting the causative mutation is a conceptual landmark shift compared to gene addition. Faithfully correcting causative mutations, though inefficient at present, is in principle the most universally applicable gene editing strategy, which moreover does not presuppose any prior knowledge of molecular disease mechanisms for therapy development. However, it is also the approach that will have the greatest problems creating revenue, as mutation-specific therapies have the same overheads as more universal approach but will have more limited patient numbers. CRISPR/Cas technology will at least help minimize development cost, as this new type of editing tools can be designed---and in many cases applied---with great ease. Conceptually, therefore, the possibilities for rare disease therapy development with these new tools and methods are near limitless and, assuming that safety concerns can be addressed, they may have tremendous impact on treatment prospects for all genetically defined rare diseases. In the following sections we summarize to what extent CRISPR/Cas-based therapeutic approaches have already been applied to rare diseases and which key improvements are required for clinical translation.

Rare Repair: Employing the Molecular Toolkit {#Sec5}
============================================

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene Therapy Studies in Numbers {#Sec6}
--------------------------------------------------------------------------------------------------

Presently only 25 registered clinical trials concern CRISPR/Cas technology, 19 of them targeting malignancies, two targeting infectious diseases, and four targeting rare diseases. The latter all concern β-hemoglobinopathies, with three aiming to treat patients (ClinicalTrials.gov identifier NCT03655678 \[[@CR141]\] and NCT03745287 \[[@CR142]\] by CRISPR Therapeutics Ltd. for β-thalassemia and sickle cell disease \[SCD\], respectively, and NCT03728322 \[[@CR143]\] by Allife Medical Science and Technology Co. Ltd. for β-thalassemia) and one aiming to use SCD focus groups to gauge knowledge, attitudes, and beliefs about clinical application of CRISPR/Cas technology (NCT03167450 \[[@CR144]\]). The focus group study and its testing the waters for CRISPR/Cas application in a patient population with exemplary palliative care amongst rare diseases indicate that numbers and representation of rare diseases in clinical trials may be about to change. To date, the number of research papers citing CRISPR in connection with 'gene therapy' has passed the 16,000 mark and in connection with 'rare disease' has passed the 1000 mark (Google Scholar), which even at this relatively early stage precludes truly comprehensive coverage of the field. This section therefore focuses on key studies that serve to illustrate current progress, be it in vitro in primary patient-derived cells and cellular disease models (Table [1](#Tab1){ref-type="table"}), animal rare disease models (Table [2](#Tab2){ref-type="table"}), or chimeric models with in vitro and in vivo data (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} with correspondingly colored entries for data in both systems).Table 1Achievements based on RNA-guided nuclease technology towards therapy development for rare diseases in human patient-derived cellsReports are sorted by disease, then by gene and disease-causing mutation. All iPSCs are of human patient-derived origin. Colored fields indicate correspondence with studies in animal models in Table [2](#Tab2){ref-type="table"}*ARG1* arginase 1, *BE* base editor, *bulk* population-wide percentages after treatment, without enrichment or antibiotic selection of corrected cells, *cDNA* complementary DNA, *clonal* percentages amongst pre-selected antibiotic-resistant clones, *DM1* myotonic dystrophy type 1, *DSB* double-strand break, *HDR* homology-directed repair, *HGVS* Human Genome Variation Society, *Hs* Homo sapiens, *HUDEP-2* human umbilical cord blood-derived erythroid progenitor cell line, *iPSC* induced pluripotent stem cell, *ITGB3* integrin beta-3, *ko* knockout, *mRNA* messenger RNA, *n/a* not available, *NHEJ* non-homologous end-joining, *NR embryos* embryos created by fusion of thalassemic fibroblast nuclei with in vitro matured enucleated oocytes, *NSG* NOD (non-obese diabetic)-SCID (severe combined immunodeficient)-*Il*2*rg*^-/-^, *TI* targeted integration, *zygotes* tripronuclear zygotesTable 2Achievements based on RNA-guided nuclease technology towards therapy development for rare diseases in in vivo studiesStudies listed are based on chimeric or transgenic animal disease models. Reports are sorted by disease, then by model. Percentage of 'correction' refers to alleles. Colored fields indicate correspondence with in vitro studies in patient-derived cells in Table [1](#Tab1){ref-type="table"}*AAV* adeno-associated virus, *AdV* adenovirus, *APTT* activated partial thromboplastin time; *cDNA* complementary DNA, *CNS* central nervous system, *FRGFah*^*--/--*^*Rag*2^*--/--*^*Il2rg*^*--/--*^, *GFP* green fluorescent protein, *HDR* homology-directed repair, *Hs* Homo sapiens, *HSPC* hematopoietic stem and progenitor cell, *iPSC* induced pluripotent stem cell, *ko* knockout, *LDLR* low density lipoprotein receptor, *MIR137* microRNA 137, *mRNA* messenger RNA, *n/a* not available, *NHEJ* non-homologous end-joining, *NOD* non-obese diabetic, *NSG* NOD (non-obese diabetic)-SCID (severe combined immunodeficient)-*Il2rg*^-/-^, *OTC* ornithine transcarbamylase, *PRKAG2* protein kinase AMP-activated non-catalytic subunit gamma 2, *RNPs* ribonucleoprotein particles, *SCID* severe combined immunodeficient, *SPF* specific pathogen-free, *ssDNA* single-stranded DNA, *TI* targeted integration, *tNGFR* truncated nerve growth factor receptor

Mutation-Specific Precision Repair {#Sec7}
----------------------------------

Correction of the causative mutation would restore the genotype of normal or at least carrier individuals (Fig. [1](#Fig1){ref-type="fig"}a). Whereas the approach may be substituted for suitable point mutations by the nascent base editing technology over time, at present it usually relies on DSB-activated HDR and is thus limited by the correspondingly low efficiency in primary cells. Notwithstanding this difficulty, the approach has been adopted for countless rare diseases for proof of principle and in exceptional studies has reached or approached clinically relevant levels of efficiency. Of the numerous studies targeting specific *HBB* mutations in SCD and β-thalassemia \[[@CR42]\], a recent publication by Dever et al. \[[@CR43]\] stands out (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, turquoise). In the study, CD34+ cells from SCD patients were electroporated with ribonucleoprotein particles (RNPs) and provided with an adeno-associated virus (AAV) donor template in order to correct the causative sickling mutation. At already high 19% HDR efficiency in bulk culture, the study employed selectable markers for fluorescence-activated cell sorting to reach 92% HDR efficiency in sorted cells. Using truncated nerve growth factor receptor (tNGFR) as the selectable marker for sorting, subsequent analyses in NSG mice allowed a long-term chimerism of 7.5% corrected cells from an initial 12%, indicating that a substantial percentage of corrected and engrafted cells were long-term repopulating cells. Moreover, the study noted a bias against long-term repopulating cells in HDR-positive cells, in line with results for zinc-finger nuclease (ZFN)-mediated HDR elsewhere \[[@CR44]\]. By contrast, an independent study recently published as preprint demonstrated over 20% correction of the *HBB*^E6V^ (sickle cell disease) mutation in patient-derived HSCs engrafted in the bone marrow of NBSGW mice after CRISPR/Cas9-mediated HDR-based editing. It further demonstrated substantial percentages of HDR-corrected cells in the erythroid compartment of the bone marrow, in part through in vivo selection of corrected cells \[[@CR45]\]. Similarly encouraging results were also achieved by De Ravin et al. \[[@CR46]\] for X-linked chronic granulomatous disease (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, yellow), who employed electroporation of RNP and a single-stranded oligodeoxynucleotide (ssODN) donor to achieve up to 21% HDR in all alleles. Functional analyses in vitro after myeloid differentiation revealed significant correction of *CYBB*-derived gp91^phox^ expression by repair of the *CYBB* premature stop codon, from background levels in negative controls up to a quarter of the percentage of gp91^phox^-positive cells seen in normal controls. These results were mirrored in vivo in NSG mice, where 15.6% of human myeloid cells were gp91^phox^-positive; once more, a quarter of the percentage seen for normal cells (65.5%). Myeloid-lineage differentiation led to an enrichment of gp91^phox^-positive cells compared with other lineages, indicating the therapeutic benefit for cell survival and a possible reduction of requirements for therapeutic bone marrow chimerism upon clinical application. Of note for many diseases with a high level of allelic heterogeneity, different mutations in compound heterozygote patients of recessive diseases may be corrected with the same RGN and donor template, as demonstrated by Xie et al. \[[@CR47]\] for two β-thalassemia mutations in the *HBB* gene: one in its promoter, and one in exon 2. Using a donor template spanning both mutations and a single RGN to target intron 1 of *HBB*, the authors corrected both mutations in induced pluripotent stem cells (iPSCs) and established functional correction after erythroid differentiation. β-Thalassemia has also served as a model disease to pioneer repair by base editing \[[@CR48]\], which gave 23% base editing efficiency for the *HBB*^*−78(A\>G)*^ mutation, and repair in human tripronuclear zygotes based on HDR \[[@CR49]\]. The latter study indicated a high error rate and highlighted the risk of off-targeting highly sequence-similar paralogs, which in this case led to off-targeting of the *HBD* gene. For many target sites such difficulties can be addressed by alternative guide RNAs and, increasingly, by alternative Cas molecules with differing protospacer adjacent motif (PAM) requirements that would help exploit minor sequence differences between paralogs. Overall, mutation-specific precision repair has seen vast improvements in efficiency and precision in long-term repopulating cells recently, to a point where its application corrects potentially therapeutic percentages of cells, in particular where therapeutic correction confers a selective advantage in chimeric or animal disease models.Fig. 1Therapeutic strategies based on CRISPR/Cas-based tools. The therapeutic use of CRISPR/Cas ribonucleoprotein complexes is wide-ranging and in its present application falls into four main categories. **a** Mutation-specific precision editing of any suitable nucleotide can be performed either by the original DNA endonuclease (double nickase) Cas9 molecule and HDR-mediated repair or by DNA base editors. This can be used to correct disease-causing mutations (green  tick) or introduce disabling sequence changes (red cross). The figure illustrates as exemplary positions (from left to right) changes in the promoter region, the coding sequence, the splice donor site, deep intronic regulatory sequences, and the splice acceptor site. **b** Sequence disruption and rearrangement can be achieved by double nickases and NHEJ-based mechanisms. Top: sequences can be disrupted by a single DSB in the promoter region, the coding sequence, the splice donor site, deep intronic regulatory sequences, and the splice acceptor site. For some applications the statistical one-third of in-frame insertion and/or deletion (indel) events for changes in the open reading frame may be corrective and exploited for therapy. Middle: pathogenic inversions in the genome can be reversed by two flanking DSBs and NHEJ-mediated re-ligation (shown). Alternatively, inversion or excision can disable pathogenic or unwanted regulatory regions (not shown). Bottom: deletions for the removal of pathogenic or unwanted regulatory regions can likewise be achieved by two flanking DSBs and NHEJ-mediated re-ligation (shown), but has also been demonstrated by an appropriately spaced pair of single nickases (not shown). **c** Targeted integration in the genome can be achieved by a single DSB and, depending on the precision required at the junctions, can employ HDR-mediated repair or NHEJ-mediated HITI. Top: insertion of a cDNA under control of an endogenous promoter is one application of targeted integration; integration in intronic sequences of the mutated gene will allow repair of mutations downstream from the DSB. Bottom: insertion of expression cassettes into safe harbor loci, such as an intergenic region (shown) or the intron of an endogene (not shown)﻿ that will allow stable transgene expression, can be used for safe gene addition. **d** Modulation of gene expression can be performed at multiple levels and may employ, from top to bottom, deactivated Cas9 fused to transcriptional regulators (e.g., in order to dynamically repress expression of pathogenic genes), deactivated Cas9 fused to epigenome modifiers (e.g., in order to permanently repress expression of pathogenic genes by DNA methylation), Cas13-like RNA-guided RNA nucleases (e.g., in order to dynamically knock down mRNA of pathogenic genes), and nuclease-deficient Cas13-like fusions to chemical RNA-base modifiers (e.g., in order to repair nonsense mutations by A\>G conversion). For clarity, epigenetic modifiers for DNA demethylation, histone acetylation, histone deacetylation, and others are not shown. Likewise, RNA base conversion for disease-causing missense mutations (such as demonstrated Ala\>Trp conversion) is not shown. Throughout, the skull indicates a pathogenic gene or molecule and the STOP sign indicates a translation termination (nonsense) codon. *ADAR2* adenosine deaminase acting on RNA 2 \[[@CR82]\], *cDNA* complementary DNA, *CRISPR/Cas* clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas), *CyD* cytidine deaminase domain for C\>U conversion in the single-stranded DNA loopout, currently with precision of ≤ 2 base pairs, *dCas9* deactivated Cas9 without endonuclease activity, *DNMT3a* catalytic domain of DNA methyltransferase 3 alpha for DNA methylation and potentially persistent repression of gene expression for affected promoters \[[@CR78]\], *DSB* double-strand break, *gRNA* guide RNA, *HDR* homology-directed repair, *HITI* homology-independent targeted integration, *indel* insertion and/or deletion, *KRAB* catalytic domain of Krüppel-associated box epigenetic repressor \[[@CR80]\], *mRNA* messenger RNA, *NHEJ* non-homologous end-joining, *UGI* uracil DNA glycosylase inhibitor domain to prevent base excision repair and removal of base edit

Therapy by Disruption or Genome Rearrangement {#Sec8}
---------------------------------------------

Generally lower efficiency and the apparent bias against long-term repopulating cells by HDR-based repair \[[@CR43], [@CR44]\] favor NHEJ-based approaches for suitable targets. Random frameshifts, disruption of toxic sequences, and genome rearrangements for deletion or inversion can be achieved by NHEJ-mediated repair and applied for therapeutic effect (Fig. [1](#Fig1){ref-type="fig"}b).

Many rare disease cases are caused by frameshift or premature stop mutations, and where the frequency of random indels leading to open reading frame (ORF) repair is sufficient, both types of mutations can be bridged by random NHEJ-based disruption. Initial proof of principle for this approach was established in Duchenne muscular dystrophy (DMD) \[[@CR50]\] based on TALEN technology, where approximately one-third of disruption events led to in-frame correction of the dystrophin gene, an outcome that at sufficiently high efficiency of delivery to target cells would be fully or partially therapeutic in DMD patients. Recent progress made in the field of gene editing in DMD is reflected in a study where AAV vectors were used to deliver CRISPR/Cas9 components intramuscularly and systemically in a canine large-animal model of DMD \[[@CR51]\]. The study demonstrated high efficacy of single-cut genome editing for restoration of dystrophin expression, reaching up to ≈ 80% of normal levels in some muscles after 8 weeks. Interestingly, in cardiac muscle, dystrophin levels in the dog receiving the highest dose reached 92% of normal. The same approach, based again on RGN technology, also succeeded in correcting mutation and phenotype in cell lines holding a naturally occurring (XCGD) frameshift mutation in the *CYBB* transgene, with similar potentially therapeutic targeting rates also for *CYBB* in its normal genomic DNA (gDNA) context \[[@CR52]\]. With 24% frequency of frameshift mutations for *CYBB* XCGD and similar contribution of frameshift mutations to epidemiology for X-linked severe combined immunodeficiency (X-SCID, *IL2Rγ* gene), Wiskott-Aldrich Syndrome (WAS, *WASP* gene), ADA-SCID (*ADA* gene), and β-thalassemia (*HBB* gene), this led the authors to argue that a quarter of patients with these disorders may be treatable with the same approach \[[@CR52]\].

Although knockout of gene function or regulatory sequences by a single RGN is mainly used for functional studies, the approach has also been applied towards therapeutic use. The possibly most significant application to date is once again in the context of β-hemoglobinopathies, where Canver et al. \[[@CR53]\] achieved high-level induction of the endogenous *HBB* paralogs *HBG1* and *HBG2*. The study employed a total of over 700 RGNs to pinpoint the erythroid enhancer of the γ-globin repressor BCL11A, and identified a highly γ-globin-inducing RGN target in one of three candidate regions. The resulting γ-globin expression potentially compensates for absence of HBB in β-thalassemia and has an additional anti-sickling effect in SCD, so that the approach may be widely applicable across β-hemoglobinopathies. The study went on to demonstrate action in SCD, using integrating lentiviral vectors (LVs) for proof of concept, in primary CD34+ cells of SCD patients and tripled the number of γ-globin-positive cells in the process. Approaches such as the one described require fundamental insights into molecular mechanisms of disease and relevant disease modifiers, but potentially cover a range of diseases or at least of different primary mutations in the case of allelic heterogeneity. They are thus more widely applicable than mutation-specific approaches and therefore more likely to be chosen for clinical translation.

Other studies have used pairs of nucleases instead of single RGNs in order to achieve potentially therapeutic outcomes. This was applied by two studies for Huntington disease \[[@CR54], [@CR55]\], possibly representative also of other dominant trinucleotide repeat disorders. Both studies employed patient-derived fibroblasts and haplotype-specific RGNs in order to disable selectively the mutant *HTT* allele. In the first case the entire mutant *HTT* gene was excised with two haplotype-selective RGNs, whereas in the second study, promoter-proximal allele-specific RGNs and a universal RGN in intron 1 of *HTT* were used to inactivate the mutant allele. In a further study, two CRISPR/Cas9 nickases either side of the *HTT* trinucleotide repeat expansion were used for its excision, although frameshift creation and employment of an allele-independent targeting approach would inactivate both *HTT* alleles in case of bi-allelic events \[[@CR56]\]. In another study for SCD therapy development, different-sized deletions/inversions in the *HBB* locus were introduced in erythroid cells in order to gauge their potential to induce γ-globin by changing the expression dynamics of the locus. The most effective RGN combination, giving a 13.6 kb inversion/deletion, was then tried in primary CD34+ cells of two SCD patients, which combined with green fluorescent protein (GFP)-based selection resulted in 32.8% and 62.2% inversion/deletion allele frequency, respectively, and a 50% reduction of sickling under low oxygen pressure as a mark of phenotypic correction \[[@CR57]\]. In another study with a focus on cystic fibrosis, three different deep intronic mutations with impact on *CFTR* splicing were excised by pairs of RGNs, an approach that resulted in restoration of correct splicing in a minigene functional assay \[[@CR58]\]. While these studies did not use technology suitable for clinical application, they served to provide solid proof of concept for paired RGN application and NHEJ-based therapy for rare diseases. Importantly, Park et al. \[[@CR59]\] (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, purple) applied pairs of RGNs designed to revert disease-causing inversion events in the *F8* gene from two different hemophilia A patients. Applying electroporation of RGNs as RNPs into urine-derived iPSC cells, the study achieved inversion efficiencies in bulk populations of 6.7% for a 1 kb inversion and of 3.7% for a 22 kb inversion. Transplantation of these cells into an *F8* hemophilia A mouse model resulted in improvement of survival time and in three of nine mice even achieving overall survival upon bleeding injury.

To conclude, NHEJ-mediated repair, although more efficient than HDR, has more limited applications, as disruption, excision, or rearrangement may not be suitable therapeutic approaches for many mutations and rare diseases. However, where the causative mutation is suitable for repair by disruption or excision, or where insights into molecular mechanisms allow the deactivation of negative disease modifiers for therapy of multiple causative mutations, efficient strategies based on NHEJ might be preferable to those based on HDR for clinical translation.

Targeted Integration {#Sec9}
--------------------

There are many cases where precise repair and disruption may both be unsuitable therapeutic approaches. First, many rare diseases with a high level of allogeneic heterogeneity cannot be addressed by modulating disease modifiers, unlike β-hemoglobinopathies. In those cases, therapy needs to cover a range of the correspondingly rare individual mutations in order to become applicable to a larger number of patients and make therapy development practicable as a commercial undertaking. Second, and a more fundamental consideration, molecular therapies for diseases caused by large deletions usually require the reintroduction of the lost genetic material. In both instances, targeted integration (TI) of expression cassettes or gene fragments would be therapeutic, given sufficiently high transfer and integration rates, and would minimize the risk of insertional mutagenesis.

A major application for TI is based on so-called safe harbor loci as integration sites that allow stable expression of the integrated transgene while not being of essence in the affected cell lineages. Moreover, this strategy can reuse effective and safe RGNs for the addition of different transgenes to the same site, which lowers the development effort for individual therapies. Besides the AAV integration site 1 (*AAVS1*) locus in human hematopoietic stem and progenitor cells (HSPCs) \[[@CR60]\], the *HPRT* gene locus has also been employed as a safe harbor locus for TI in human cells \[[@CR61]\], as has the chemokine (CC motif) receptor 5 (*CCR5*) \[[@CR62]\], and the popular murine *ROSA26* locus has also found its ortholog in the human genome \[[@CR63]\]. TI strategies that disrupt *HPRT* function can additionally enrich modified cells by selection against non-integrants with 6-thioguanine in vitro \[[@CR64]\] and, with mixed results, in vivo \[[@CR64], [@CR65]\]. In a deviation from the safe harbor principle, co-targeting of the *HPRT* locus can also be used for chemical selection in order to enrich for editing events at independent loci, which have a high level of co-occurrence \[[@CR61]\]. Whereas *AAVS1* and *HPRT* are used for insertion of autonomous expression cassettes, *ROSA26* and *CCR5* can be employed to achieve expression of transgenes from the endogenous control elements of the locus \[[@CR63], [@CR66], [@CR67]\]. Regarding the *AAVS1* site, in a seminal study employing ZFNs for gene therapy of X-SCID, fine-tuning of conditions allowed between 3 and 6% efficiency of HDR-based integration in primitive to early HSPCs \[[@CR44]\]. TI at the *AAVS1* site was also exploited in a study for hemophilia B therapy development, which employed urine-derived hemophilia B iPSCs for in vitro and in vivo evaluation \[[@CR68]\] (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, green). In short-term follow-up in immunodeficient mice, iPCS-derived cells with *AAVS1* integration of a human elongation factor 1α (EF1α)-promoter-driven F9 complementary DNA (cDNA) achieved eight-fold induction of serum F9 levels compared to integration-free control cells. Recently, conditions were refined for RGN-mediated *AAVS1*-TI, and it was found that excluding Cas9 expression from G1 phase of the cell cycle significantly enhanced HDR-mediated integration at the locus \[[@CR69]\]. The *HPRT* locus served as safe harbor for therapy in iPSCs of a patient with *ARG1*-linked urea cycle disorder \[[@CR70]\]. The strategy targeted exon 1 of *HPRT* for integration of a construct holding both a puromycin resistance expression cassette and an *ARG1* cDNA driven by the EF1α promoter. This allowed selection of HPRT disruption and of puromycin resistance to give between 46 and 92% of normal arginase messenger RNA (mRNA) levels in undifferentiated iPSCs; this was decreased, however, to between 27 and 39% upon hepatic differentiation. Finally, the murine *ROSA26* locus was recently used for TI after adenoviral delivery of RGNs and a human α-1-antitrypsin HDR donor into the liver of wild-type mice \[[@CR71]\], which achieved overall allele frequencies in the liver of between 5 and 26% as a tentative basis for therapy of human α-1-antitrypsin deficiency. Of note, *AAVS1* encodes the phosphatase 1 regulatory subunit 12C (*PPP1R12C*), also known as the myosin binding subunit 85 (*MBS85*), and, as for CCR5, the exact importance of the gene encoded at this locus is not yet known \[[@CR62]\]. Many transgenes can interfere with splicing of *PPP1R12C* transcripts \[[@CR67]\], and a study investigating TI at the *AAVS1* locus detected a change in cellular contractile force, implying that at least for the treatment of myopathies, *AAVS1* may not be an inert safe harbor locus after all \[[@CR72]\]. Therefore, studies to date on what might be more generally called 'standard loci for TI' indicate the scope for reapplying the corresponding tools in a modular fashion for safe integration, selection, or ubiquitous expression in therapy development for rare diseases, while also highlighting that suitability of each locus needs to be examined on a case-by-case basis.

A further application for TI is integration in the mutant locus itself, in order to exploit endogenous transcriptional control elements and, for gain-of-function mutations, to inactivate a potentially toxic mutant while adding a functional copy. The former strategy was pursued in the original ZFN-based study for X-SCID in parallel to using the *AAVS1* safe harbor locus and in a follow-up study was also extended to RGN-mediated integration into the *IL2RG*^*R226H*^ mutant gene \[[@CR73]\]. Using RNP electroporation and AAV delivery of the donor template, the latter study achieved 50% reporter-positive committed hematopoietic progenitors (CD34+CD133−) and 25% reporter-positive primitive hematopoietic stem cells (CD34+CD133+CD90+). Both studies used the endogenous locus and promoter to drive cDNA expression of a partial *IL2RG* cDNA, but in one of many improvements to the previous study \[[@CR44]\], the more recent work employs a cDNA and integration site downstream of exon 1 (instead of exon 4), suitable for repair of any causative *IL2RG* mutation from exon 2 onwards \[[@CR73]\]. A similar approach was also employed in a study for haemophilia B, where CRISPR/Cas9 and an HDR donor DNA were used to knock a full-length human *F9* cDNA into exon 1 of the *F9* endogene in iPSCs from two hemophilia B patients. These corrected iPSCs were differentiated into hepatocyte-like cells (HLCs) and transplanted into hemophilic mice, where they achieved engraftment, expansion, and production of F9 at therapeutic levels 6--9 months after transplantation \[[@CR74]\].

Studies on TI based on RGNs are still infrequent, but bound to proliferate with the continuously improving efficiency of the approach. The original concept of efficient TI is dependent on RGN application with high general HDR efficiency, which amongst other improvement strategies may be increased five-fold by silencing of NHEJ components \[[@CR75]\]. However, the more recent approach of homology-independent TI (HITI) \[[@CR76]\] relies on NHEJ and may increase TI efficiencies considerably for many applications. With ongoing development and wide scope for therapeutic application \[[@CR77]\], HITI as an approach for higher-efficiency TI may therefore turn out to be an important addition to the rare disease therapy toolkit.

Modulation of Gene Expression {#Sec10}
-----------------------------

A plethora of tools based on CRISPR/Cas technology have already been developed that allow control of gene expression, and transcriptional regulators as well as RNA editors have already been used towards rare disease therapy. Both technologies have the clear disadvantage that for curative therapy development permanent integration or lifelong repeat application would be required, even though AAV-based approaches can show persistence of expression over several months. The recent development of epigenome editing tools to our knowledge still awaits its application to rare diseases, but results in modifications that appear permanent and therefore potentially suitable for curative therapy. This is the case at least for DNA modification, with as yet conflicting results for the persistence of histone modifications and their causative effect on gene repression \[[@CR78]\].

Potential disease-specific application of transcriptional modulation was demonstrated for *PCSK9*-linked familial hypercholesterolemia in a study that employed a nuclease-deactivated Cas9 (dCas9) linked to the Krüppel-associated box epigenetic repressor (KRAB) motif and achieved significant knockdown of *Pcsk9* mRNA in mouse liver \[[@CR79]\]. The study further showed maintenance of significant knockdown after double-hit delivery by AAV vectors for at least 168 days, and also a transient peak of treatment-specific liver damage, as measured by elevated alanine transaminase (ALT) serum levels. Moreno et al. \[[@CR80]\] employed a split Cas9 system based on two AAV vectors in order to increase targeting capacity for transcriptional regulation and demonstrated its utility in a murine model of retinitis pigmentosa. Using a KRAB fusion as a transcriptional repressor and a VP64 + rTA fusion as transcriptional activator, the study achieved effective reprogramming of photoreceptor types in vivo first in normal mice and then in the rd10 murine model of autosomal recessive retinitis pigmentosa. In the latter, transcriptional repression of *Nrl* effectively converted rod- to cone-like receptors, prevented photoreceptor degeneration, and 6 weeks after injection gave significantly higher visual acuity for all eyes injected.

Therapeutic relevance of RNA knockdown was demonstrated for frontotemporal dementia with parkinsonism using the compact Cas13d-derived CasRx system \[[@CR81]\]. AAV delivery of CasRx to patient-derived iPSCs significantly reduced the pathologically elevated ratio of the 4R and 3R isoforms of tau (encoded by *MAPT*) to 50% of mock-treated control value, while healthy controls showed 20--30% of control value. The same study also demonstrated absence of double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA) cleavage as a safety feature, and the ability of CasRx to process an array of multiple guide RNAs for multiplexed targeting of endogenous RNA from the same construct.

A landmark study by Cox et al. \[[@CR82]\] employed a deactivated Cas13 (dCas13) fused to an adenosine deaminase acting on RNA 2 (*ADAR2*) catalytic domain in order to repair pathogenic mutations at the RNA level. Effective A\>G base conversion and reversion of nonsense mutations was demonstrated for pathogenic transcripts implicated in X-linked nephrogenic diabetes insipidus (*AVPR2* ^*W293\**^ at up to 35% efficiency) and Fanconi anemia (*FANCC*^*W506\**^ at up to 22% efficiency) as full-length transcripts in transiently transfected HEK293T cells, and was also detected above 20% efficiency for an additional nine of 34 partial transcripts tested, including nonsense mutations of *MEPCP2* (Rett syndrome), *ADGRV1* (Usher syndrome type 2C), *AHI1* (Joubert syndrome 3), *PRKN* (Parkinson disease 2), *COL3A1* (Ehlers-Danlos syndrome type 4), *BRCA1* (breast--ovarian cancer, familial 1), *MYBPC3* (primary familial hypertrophic cardiomyopathy), *APC* (familial adenomatous polyposis 1), and *BMPR2* (primary pulmonary hypertension).

Evidently, CRISPR/Cas technology has moved beyond gene editing and allows flexible and precise modification of the epigenome and the transcriptome. Its versatility and developments such as the use of dCas9 or small Cas13 derivatives in combination with additional functional domains will accelerate basic research into transcriptional, epigenome, and RNA-level regulation of gene expression, besides contributing tools for translational medicine. The early findings discussed here showcasing such modular use of CRISPR/Cas technology demonstrate that therapy of rare diseases will have its fair share of benefit, but that certain aspects such as efficiency and permanence of treatment still need to be addressed.

Using the Right Tool for the Job {#Sec11}
--------------------------------

The versatility and ease of use of CRISPR/Cas technology and its derivatives have speedily led to the development of a still expanding battery of diverse tools and approaches to tackle disease. In this currently fast-moving field, a key dilemma for researchers working on therapy development for rare diseases is their need to initiate their work in the present with a definite choice of tools and approaches for their disease of interest, despite the risk that their choice might appear outdated in the near future.

The unique molecular, pathophysiological, and clinical characteristics of the disease of interest will be a determining factor in the choice of therapeutic strategy, where such knowledge exists. However, and towards eventual translation to the clinic, consideration of the number of potentially treatable patients with a given approach also needs to be given adequate weight in the choice of treatment strategy. Should a mutation-specific approach be employed, should a targeted insertional approach be employed instead, in order to cover a range of disease-causing alleles, or might the latter also be achieved by manipulation of mutation-independent disease modifiers? Other than for large deletions or rearrangements as causes of disease, mutation-specific precision repair will be universally applicable as a treatment approach, wherever patient numbers and efficiency of correction are suitable. For loss-of-function mutations, knock-in of functional cDNA or of gene fragments in the defective endogene or targeted gene addition of expression cassettes in safe harbor loci might be feasible approaches. For gain-of-function mutations, knock-in into and deactivation of the defective endogene would once again be suitable, as would disease-allele-specific disruption, transcriptional inactivation, or RNA knockdown. Where the required nucleotide change is suitable, the quickly evolving approach of DNA base editing might provide a safer option than DSB-based precision repair, whereas RNA base editing might provide transient and safer alternatives to DNA precision repair or disruption instead.

The molecular strategy, however, is only one of the choices to be made. For delivery of CRISPR/Cas tools, selecting in vivo or ex vivo application and the choice of vector type and administration routes will depend on clinical phenotypes and accessibility and type of affected tissues. Choice of timing, too, is of great importance when treating chronic and progressive diseases, so as to maximize therapeutic benefit while minimizing risks. The treatment delivery timepoint is crucial but often uncertain, as gene editing applied too late may not be able to repair established damage, whereas premature application, such as of gene silencing CRISPR/Cas treatments, may lead to unexpected and deleterious gene dysfunctions \[[@CR83], [@CR84]\]. More importantly, each study has to calculate the risks cautiously and independently for each patient, in order to define the acceptable level of risk in the pursuit of a cure. Finally, informative trial design, suitable manufacturing of reagents, and the potential for commercialization all need to be considered, before even the most ingenious molecular strategy may translate into a successful therapy for rare disease patients.

Rare Trends: Clinical Translation for Rare Diseases is Taking Off {#Sec12}
=================================================================

From Shakedown to Maiden Voyage {#Sec13}
-------------------------------

There are still many unknowns in the therapy development for rare diseases based on CRISPR/Cas technology. With the field developing at a staggering pace, it is unclear how well current cutting-edge technology in terms of off-target effects, efficiencies of delivery, and efficiencies of cell-autonomous correction will stand up to comparison 10 or even 2 years down the line. After all, safety standards and assumptions from the early days of gene addition, made by professionals no less diligent than those involved in gene editing today, appear naïve in retrospect. The correspondingly risky application of the fledgling CRISPR/Cas technology has thus been spearheaded by application to cancer, and the first-in-man Chinese CRISPR/Cas application to a lung cancer patient in 2016, only 3 years after the technology was first used in eukaryotic cells, is already history \[[@CR85]\]. Meanwhile, researchers and clinicians dealing with less acute diseases rightly chose to err on the side of caution. Whereas the current generation of RGN therapeutics for ex vivo application is fully characterized for off-target activity and can be delivered efficiently in virus- and DNA-free fashion, new studies continue to uncover potentially problematic aspects of DSB-related technologies. Application in vivo faces additional challenges of delivery and safety, some of which will be hard to address in murine or chimeric models. Differences in size, longevity, cytokine microenvironments, and specific DNA and RNA sequences are only some parameters that may interfere with meaningful analysis and interpretation of results and will necessitate research in larger models, non-human primates or, for what remains unknown once all preclinical tests are passed, clinical trials.

Flight Plan {#Sec14}
-----------

With the advent of CRISPR/Cas and the ongoing progress of gene therapy clinical trials in general, companies involved in rare disease therapy development have multiplied over the last years \[[@CR86]\], and with the accessibility of the technology, even crowdfunding for smaller biotech companies is considered an option \[[@CR87]\]. The three leading companies in the field of CRISPR/Cas pharmaceuticals, CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine, 4 years after their initial funding and 2 years after going on the stock exchange, are pushing forward ambitious programs for rare disease therapy development in the USA and Europe. The product pipelines for non-malignant, non-infectious disorders read like a who-is-who of prominent rare diseases, with ongoing addition and removal of candidate diseases for early-stage development (Table [3](#Tab3){ref-type="table"}). To date, and as a first for CRISPR/Cas application to rare diseases, CRISPR Therapeutics is recruiting for a clinical phase I/II trial for β-hemoglobinopathies with its *CTX001* product in Germany and the UK (NCT03655678 \[[@CR141]\]), with an initial cohort of 12 patients, extendable up to 45. A suspension put on the trial by the US Food and Drug Administration (FDA) was lifted on 10 October 2018 \[[@CR88]\], a development that, while opening up parallel trial initiation in the USA, indicates persistent uncertainties about the safety of the technology and the dissemination of related information.Table 3Rare disease product pipelines of leading companies based on clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas)  technologyOnly product development for non-malignant diseases is listed, sorted by rare disease. Information has been extracted from the product pipelines given on the company websites of CRISPR Therapeutics \[[@CR138]\], Editas Medicine \[[@CR139]\], and Intellia Therapeutics \[[@CR140]\], last update 22 November 2018. Recent changes in the portfolio, as indicated, suggest ongoing readjustments of early-stage targets, which may also affect current portfolio content or result in additional disease targets in the future*AAV* adeno-associated virus, *CRSP* CRISPR Therapeutics, *EDIT* Editas Medicine, *HDR* homology-directed repair, *LNP* lipid nanoparticle, *n/a* not available, *NHEJ* non-homologous end-joining, *NTLA* Intellia Therapeutics, *RNP* ribonucleoprotein particle

Ethical Turbulence {#Sec15}
------------------

Although CRISPR/Cas-related research publications for rare diseases are proliferating, commercial exploitation of promising approaches is making it increasingly difficult to survey and critically assess cutting-edge translational progress. As development switches from academic laboratories to biotech and pharmaceutical companies, so does dissemination of results from peer-reviewed articles to business statements and announcements on websites. Therefore, the good news for patients that investment in gene therapy is booming \[[@CR89]\] has the flipside that increasingly frequent conflicts of interest in research interfere with unbiased dissemination of methods and results, endangering current governance structures and possibly long-term trust in the technology \[[@CR90]--[@CR92]\]. As a prominent example, preprint publication in early 2018 of the pre-existing population-wide immunity against Cas9 proteins \[[@CR33]--[@CR35]\] prompted market upheaval in CRISPR/Cas-related stocks and the declaration that the problem had already been investigated and found to be no impediment to therapeutic application \[[@CR93], [@CR94]\]. Be that as it may, early dissemination of related findings would have been better for overall trust in the technology and in the integrity of those involved in their commercial development. Similarly, full disclosure of methodology and results for analyses of off-target and recombination events would help establish trust in the technology and the safety of prospective trials, given that it is unclear whether such analyses have taken into account the latest developments in the field. For instance, off-target assessment often relies on amplification of areas closely flanking the sites of interest, and such assessment would miss long-distance recombination events recently found to be triggered even by single-DSB approaches \[[@CR39]\]. The ongoing withdrawal of frontline developments from peer review and from independent experimental confirmation is therefore a concrete problem ethically as well as---it turns out---commercially. Whereas secrecy is therefore a major concern of the field, another still more pressing concern is the erosion of ethical boundaries in the clinical application of CRISPR/Cas technology \[[@CR95]\]. Recent reports of the birth of CRISPR/Cas-edit twins, engineered to prevent infection by HIV from their father \[[@CR96]\], indicate an absence of checks and balances in the application of CRISPR/Cas at one if not more institutions equipped to apply the technology to human embryos, and a possibly wider and worrying loss of perspective in the assessment of risks and benefits for human life.

Budget Travel {#Sec16}
-------------

Gene addition approaches by ex vivo therapy are costly to implement, and drug companies struggle to switch business models for inherited diseases from lifelong drug-based management to one-off curative treatments. A contributing factor to the recent sale of GlaxoSmithKline's gene therapy portfolio to start-up company Orchard Therapeutics might therefore have been the significant price tag of potential treatments. For the approved orphan drug Strimvelis® for ADA-SCID, which is based on retroviral gene addition, this is a significant €594,000 per patient \[[@CR97]\]. However, beyond the suffering prevented by this curative treatment, the cumulative cost of palliative treatment is several-fold this cost. What is more, non-viral ex vivo delivery for RGNs, and in particular in vivo delivery, might make one-shot therapies easier and cheaper to implement. A significant development here is the potential transformation of gene therapy centers from good manufacturing practice (GMP) containment facilities to closed-circuit GMP devices in a clean room, at least for disorders treatable by HSPC transplantation. Addition of an in-line lentiviral transduction module to the Miltenyi CliniMACS Prodigy^®^ device for isolation of HSPCs in a recent Fanconi anemia trial more than halved the personnel and time requirements for treatment \[[@CR98]\]. An alternative module for electroporation of RNPs and HDR donors allows analogous simplification of infrastructure and procedures also for CRISPR/Cas delivery \[[@CR98]\]. The machine would make a clinical gene therapy program for suitable disorders widely affordable and traditional GMP facilities at times obsolete \[[@CR99]\]. Another emerging technology, in utero gene therapy, may change not only the cost and accessibility of rare disease treatments, but would moreover increase efficiency of treatment and expand the range of disorders to which gene therapy may be applicable \[[@CR100]\]. The risk of inadvertent germline transmission and the inability to predict possible success in human application from experimental models are concerns en route to clinical translation, but the landmark drop in required vector amounts and treatment cost, and, more fundamentally, the applicability to early-onset and prenatally lethal disorders, would be another game changer for gene therapy. Ongoing research into possible complications of treatment \[[@CR101]\], improvements to efficiency \[[@CR102]\], and successful tests in non-human primates, such as those for treatments of hemophilia B \[[@CR103]\] and Gaucher disease \[[@CR104]\], may help overcome bioethical and regulatory hurdles in implementing the technique for rare diseases.

Not a Trip, But a Journey {#Sec17}
-------------------------

It therefore seems that rare diseases and CRISPR/Cas technology are going places together, albeit with choices and uncertainties ahead and with the constant need to maintain an open scientific culture and safeguard ethical boundaries for its clinical application. CRISPR/Cas-based technology, newly derived tools, and ongoing auxiliary improvements to delivery methods, including GMP-in-a-box and in utero delivery, have great potential to transform and democratize gene therapy for rare diseases. Mutation-specific cures may thus become affordable, even for small patient cohorts, and allow restoration of normal or carrier genotype as the most immediate and effective therapy. Increasingly efficient manipulation of adult stem cells has already made them the safe substrate of choice for much of CRISPR/Cas-based therapy development for rare diseases and sidelined the approach of editing and clonally selecting iPSCs, which still pose safety concerns for clinical application \[[@CR105]\]. Ongoing improvements to efficiencies of CRISPR/Cas-based tools and approaches and refined use of inert human markers, such as tNGFR \[[@CR43]\], may further endorse the use of adult stem cells and will encourage still wider adoption of CRISPR/Cas editing technology. In parallel, increasing affordability and application of massively parallel sequencing not only accelerates the discovery of new therapy targets for rare diseases, but applied to CRISPR/Cas also helps delineate off-target and recombination events associated with treatment. It appears that the most comprehensive currently available analysis methods allow us to fully characterize existing CRISPR/Cas-based tools for DNA-level efficiency and safety, while a switch to the most efficient of the high-specificity RGN variants \[[@CR106]--[@CR108]\] will likely become routine for new commercial research and development. Gene editing as version 2.0 of gene therapy has been accelerated enormously by the young CRISPR/Cas technology. Precision editing, targeted disruption, rearrangement and integration, and modulation of gene expression based on the CRISPR/Cas platform already offer staggering possibilities for gene therapy development and, given the current impetus, the repertoire of tools and approaches for rare disease gene therapy will continue its rapid expansion. As further CRISPR/Cas-based gene therapies enter clinical trials for rare diseases, versions 2.1 and higher will always be just around the corner.
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